Impact of laboratory practices on interlaboratory variability in therapeutic drug monitoring of immunosuppressive drugs

Therapeutic Drug Monitoring

Volumn 37, Issue 6, 2015, Pages 718-724

  Christians, Uwe ^a   Vinks, Alexander A ^b   Langman, Loralie J ^c   Clarke, William ^d   Wallemacq, Pierre ^f   Van Gelder, Teun ^g   Renjen, Varun ^h   Marquet, Pierre ^e   Meyer, Eric J ⁱ  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c MAYO CLINIC   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e LIMOGES UNIVERSITY HOSPITAL   (France)

^f CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^g ERASMUS MEDICAL CENTER   (Netherlands)

^h Navigant Consulting Inc   (United States)

ⁱ NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Good laboratory practices; Immunoassay; Immunosuppressants; Interlaboratory variability; International survey; LC MS MS; Personnel training; Standardization; Therapeutic drug monitoring

Indexed keywords

ASCOMYCIN; CYCLOSPORIN; EVEROLIMUS; IMMUNOSUPPRESSIVE AGENT; ISOTOPE; MYCOPHENOLIC ACID; RAPAMYCIN; TACROLIMUS;

ARTICLE; CLINICAL LABORATORY; CONSENSUS; CONTROLLED STUDY; DATA COLLECTION METHOD; DRUG MONITORING; DRUG SURVEILLANCE PROGRAM; GOOD LABORATORY PRACTICE; HEALTH CARE QUALITY; HEALTH SURVEY; HUMAN; IMMUNOASSAY; IMMUNOSUPPRESSIVE TREATMENT; ISOTOPE LABELING; LABORATORY TEST; LIQUID CHROMATOGRAPHY TANDEM MASS SPECTROMETRY; MEDICATION COMPLIANCE; MULTICENTER STUDY; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY CONTROL; STANDARDIZATION; TANDEM MASS SPECTROMETRY; DOSE RESPONSE; INTERNET; LIQUID CHROMATOGRAPHY; ORGAN TRANSPLANTATION; PROCEDURES; PROTOCOL COMPLIANCE; QUESTIONNAIRE; SPECIMEN HANDLING; STANDARDS;

CHROMATOGRAPHY, LIQUID; CLINICAL LABORATORY TECHNIQUES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; GUIDELINE ADHERENCE; GUIDELINES AS TOPIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERNET; LABORATORY PROFICIENCY TESTING; ORGAN TRANSPLANTATION; SPECIMEN HANDLING; SURVEYS AND QUESTIONNAIRES; TANDEM MASS SPECTROMETRY;

EID: 84947917277     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0000000000000205     Document Type: Article

References (18)

1. Wavamunno MD, Chapman JR. Individualization of immunosuppres-sion: concepts and rationale. Curr Opin Organ Transplant. 2008;13: 604-608.
2. Oellerich M, Armstrong VW. The role of therapeutic drug monitoring in individualizing immunosuppressive drug therapy: recent developments. Ther Drug Monit. 2006;28:720-725.
3. Kuypers DR. Immunosuppressive drug monitoring-what to use in clinical practice today to improve renal graft outcome. Transpl Int. 2005;18: 140-150.
4. Wallemacq PE. Therapeutic monitoring of immunosuppressant drugs. Where are we? Clin Chem Lab Med. 2004;42:1204-1211.
5. Holt DW. Therapeutic drug monitoring of immunosuppressive drugs in kidney transplantation. Curr Opin Nephrol Hypertens. 2002;11:657-663.
6. Morris RG. Immunosuppressant drug monitoring: is the laboratory meeting clinical expectations? Ann Pharmacother. 2005;39:119-127.
7. Levine DM, Maine GT, Armbruster DA, et al. The need for standardization of tacrolimus assays. Clin Chem. 2011;57:1739-1747.
8. Annesley TM, McKeown DA, Holt DW, et al. Standardization of LC-MS for therapeutic drug monitoring of tacrolimus. Clin Chem. 2013;59: 1630-1637.
9. Meyer EJ, Schniedewind B, Boucher R, et al. Cross-validation of ever-olimus LC-MS/MS and Thermo Fisher QMS therapeutic drug monitoring assays-the Zortracker Cross-Validation and TDM Support Program. Ther Drug Monit. 2013;35:702.
10. Code of Conduct: The Market Research Society. London, UK; 2012. Available at: www.mrs.org.uk/pdf/code of conduct (2012 rebrand).pdf. Accessed October 16, 2014.
11. Bowers LD, Mathews SE. Investigation of the mechanism of peak broadening observed in the high-performance liquid chromatographic analysis of cyclosporine. J Chromatogr. 1985;333:231-238.
12. Taylor PJ, Brown SR, Cooper DP, et al. Evaluation of 3 internal standards for the measurement of cyclosporin by HPLC-mass spectrometry. Clin Chem. 2005;51:1890-1893.
13. Taylor PJ. Internal standard selection for immunosuppressant drugs measured by high-performance liquid chromatography tandem mass spec-trometry. Ther Drug Monit. 2007;29:131-132.
14. Korecka MA, Patel R, Shaw LM. Evaluation of performance of new, isotopically labeled internal standard ([13c2d4]RAD001) for everolimus using a novel high-performance liquid chromatography tandem mass spectrometry method. Ther Drug Monit. 2011;33:460-463.
15. Napoli KL. Organic solvents compromise performance of internal standard (ascomycin) in proficiency testing of mass spectrometry-based assays for tacrolimus. Clin Chem. 2006;52:765-766.
16. Wallemacq P, Armstrong VW, Brunet M, et al. Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European consensus conference. Ther Drug Monit. 2009;31:139-152.
17. Holt DW, Armstrong VW, Griesmacher A, et al. International Federation of Clinical Chemistry/International Association of Therapeutic Drug Monitoring and Clinical Toxicology working group on immunosuppres-sive drug monitoring. Ther Drug Monit. 2002;24:59-67.
18. Oellerich M, Armstrong VW, Schütz E, et al. Therapeutic drug monitoring of cyclosporine and tacrolimus. Update on Lake Louise Consensus Conference on cyclosporin and tacrolimus. Clin Biochem. 1998;31: 309-316.